0001209191-19-012998.txt : 20190225 0001209191-19-012998.hdr.sgml : 20190225 20190225164026 ACCESSION NUMBER: 0001209191-19-012998 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190221 FILED AS OF DATE: 20190225 DATE AS OF CHANGE: 20190225 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: GREGORY JULIA P CENTRAL INDEX KEY: 0001226675 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38080 FILM NUMBER: 19630081 MAIL ADDRESS: STREET 1: 8800 TECHNOLOGY FOREST PLACE CITY: THE WOODLANDS STATE: TX ZIP: 77381 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Biohaven Pharmaceutical Holding Co Ltd. CENTRAL INDEX KEY: 0001689813 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: D8 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 215 CHURCH STREET CITY: NEW HAVEN STATE: CT ZIP: 06510 BUSINESS PHONE: 203-404-0410 MAIL ADDRESS: STREET 1: 215 CHURCH STREET CITY: NEW HAVEN STATE: CT ZIP: 06510 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-02-21 0 0001689813 Biohaven Pharmaceutical Holding Co Ltd. BHVN 0001226675 GREGORY JULIA P C/O BIOHAVEN PHARMACEUTICALS, INC. 215 CHURCH STREET NEW HAVEN CT 06510 1 0 0 0 Common Shares 2019-02-21 4 M 0 12000 23.63 A 12000 D Common Shares 2019-02-21 4 S 0 12000 43.56 D 0 D Stock Option (Right to Buy) 23.63 2019-02-21 4 M 0 12000 0.00 D 2027-08-01 Common Shares 12000 24000 D This exercise and the subsequent sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 22, 2019. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.20 - $44.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. This option grant was made pursuant to the Issuer's non-employee director compensation policy. The common shares underlying this option vest in three equal installments on August 2, 2018, 2019 and 2020, subject to the Reporting Person's continuous service with the Issuer at each vesting date. /s/ Darren DeStefano, Attorney-in-Fact 2019-02-25